Federal judge tosses out antitrust lawsuit against Eli Lilly, Sanofi over diabetes drug discounts

A fed­er­al judge in New York dis­missed an an­titrust law­suit against drug­mak­ers al­leg­ing that they con­spired to boost prof­its by lim­it­ing dis­counts on in­sulin be­gin­ning in 2020.

Mo­sa­ic Health and Cen­tral Vir­ginia Health Ser­vices, both non­prof­it health­care providers, filed the law­suit in 2021 in the US Dis­trict Court for the West­ern Dis­trict of New York. They al­leged that Sanofi-Aven­tis, Eli Lil­ly, No­vo Nordisk and As­traZeneca broke state and fed­er­al laws by “sud­den­ly, and in co­or­di­na­tion with one an­oth­er,” agree­ing to lim­it drug dis­counts through the fed­er­al 340B pro­gram, which al­lows safe­ty-net hos­pi­tals and clin­ics to buy drugs like in­sulin at cheap­er prices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.